Yes, that is definitely a downside of statins. But something that can be managed. We are lucky that we now have PCSK-9 inhibitors. That is my ace in the hole. But it would not be covered by insurance. I would love to see another 60% price reduction but I doubt that will happen.

1 Like

You can always consider the Indian Pharmacy option… PCSK-9 inhibitors seem to be around $200/month currently: (82 rupees to the US dollar).

2 Likes

Oh, I will definitely do that!

GoodRX pricing on Repatha in the US is about $600/month vs. $200 in India, so there is your 60% reduction in price :smile:

5 Likes

And more news related to statins:

Statin Response Varies by Age

TOPLINE:

Older adults may respond to low- to moderate-intensity statin therapy more than younger patients do, according to a study published online July 31 in Annals of Internal Medicine.

METHODOLOGY:

  • Researchers analyzed data from 83,958 adults in Denmark who started taking simvastatin or atorvastatin between 2008 and 2018.
  • 12% were age 75 or older, and 16% were younger than 50 years.

TAKEAWAY:

  • With 20 mg of simvastatin, the older group had a greater percentage reduction in low-density lipoprotein cholesterol (LDL-C) than did the younger group (39% vs 33.8%).

  • With 20 mg of atorvastatin, the decreases in LDL-C were 44.2% and 40.2%.

  • Adjusted analyses found that low- to moderate-intensity treatment led to an additional LDL-C reduction of 2.62 percentage points in older patients.

  • The association was similar for primary and secondary prevention but smaller for high-intensity treatment. With 80 mg of atorvastatin, there was a 0.58-point difference between groups.

https://www.medscape.com/viewarticle/995010

3 Likes

And, speaking of APO-B …

4 Likes

You really need to watch all three episodes of that podcast. It’s about seven hours.

2 Likes

Date night with Thomas Dayspring. Watch on 2 x speed.

3 Likes

Apparently it isn’t a thing in the U.S anymore to keep taking liver tests. A couple times seems enough for most.

https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs

3 Likes

I was wondering the other day, should one really take longevity advice from a doctor that is overweight, has CAC score >300 and walks with a walking stick in his mid seventies?

1 Like

The advice is about lipids and with any doctor you need to know which research papers he or she refers to.

1 Like

You’re judging their intelligence and/or knowledge by their appearance and medical conditions?

1 Like

image

There are many people who give good advice without actually following it themselves.
Athletic coaches are a good example. Dayspring backs up his arguments.

2 Likes

One needs to understand how remarkably difficult it is to lose weight. If you haven’t read it, I recommend the book “The Hungry Brain”. It’s also very difficult to undo the genetic traits you inherit.

1 Like

When has Dayspring ever given “longevity” advice if there is such a thing? If you want information about lipids or how to protect against CVD, then yes. You should listen to everything he says. It is his bad luck that he cannot tolerate statins or ezetimibe.

3 Likes

But, then again, he could practice time-restricted feeding, which is probably his best bet.
When you are very socially active and participate in many seminars etc. it is tough to keep from gaining weight.

1 Like

He does time restricted feeding and a low carb diet. I mean, he’s cared for by Peter Attia what else would you expect. He was also on PCSK-9 inhibitors as soon as they were released 9 years ago.

1 Like

Not judging and questioning the science just pointing at the fact that he did / does not really accommodate much importance on lifestyle interventions and clearly he does not seem to believe they are as important factors in ASCVD for himself and that his advice should be considered trough this optics. That any medical interventions should be second to lifestyle. Nothing else.

1 Like